TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29107495

Group type: EXPERIMENTAL
Intervention: Oral TXA (2 g orally 2 hours preoperatively)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (20 mg/kg intravenous bolus 5 minutes before incision)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Topical TXA (2 g applied topically)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral TXA
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intravenous TXA
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Topical TXA
Number of subjects: 180

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 180
Study: 27480965

Group type: EXPERIMENTAL
Intervention: NSAID Before Food (BF)
Number of subjects: 160

Group type: COMPARATOR
Intervention: NSAID After Food (AF)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: NSAID BF for 2 days then AF for next two days (CO-1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: NSAID AF for 2 days then BF for next two days (CO-2)
Number of subjects: 160
Study: 24608161

Group type: EXPERIMENTAL
Intervention: GnRH agonist (Goserelin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GnRH agonist + GnRH antagonist (Goserelin and Cetrorelix)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study: 22568450

Group type: EXPERIMENTAL
Intervention: High stress coping capacity with spinal anaesthesia
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Low stress coping capacity with spinal anaesthesia
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 162

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 162
Study: 20837645

Group type: EXPERIMENTAL
Intervention: Fasted exercise training (F; n = 10)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Carbohydrate-fed exercise training (CHO; n = 10)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CON; n = 7)
Number of subjects: 27
Study: 17664499

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)‐type intervention plus a consultation letter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual clinical care plus a consultation letter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)‐type intervention
Number of subjects: 0
Study: 16224161

Group type: EXPERIMENTAL
Intervention: CAPD patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CAPD patients with carotid artery calcified plaques
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 25
Study: 12105840

Group type: EXPERIMENTAL
Intervention: rFVIIa (4 doses: 5, 20, 80, and 120 microg/kg)
Number of subjects: 71
Study: 9917477

Group type: EXPERIMENTAL
Intervention: Quality improvement initiatives through the Vermont Oxford Network, including the NIC/Q Project and NIC/Q 2000, involving 34 NICUs over 2 years.
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Confidential quarterly and annual reports based on the Network database.
Number of subjects: 25000
Study: 8560329

Group type: EXPERIMENTAL
Intervention: Schizophrenia (acute and chronic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schizomania and acute schizophrenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mania
Number of subjects: 0
Study: 2087535

Group type: EXPERIMENTAL
Intervention: Growth hormone releasing factor (GRF) 1 microgram/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 284710

Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) at doses of 0.10, 0.15, and 0.20 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) at a dose of 0.06 mg/day
Number of subjects: 0
Study: 31174547

Group type: EXPERIMENTAL
Intervention: Altering the order of foods ranked in ascending order of SFA content (n = 261)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Offering swaps to a product with less SFA (n = 279)
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Combined intervention of altering order and offering swaps (n = 273)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: No intervention (control group, n = 275)
Number of subjects: 1088
Study: 27943410

Group type: EXPERIMENTAL
Intervention: Dedicated ultrasound rotation (2-week curriculum)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Medical school ultrasound rotation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Weeks in the emergency department as a resident
Number of subjects: 33
Study: 25536535

Group type: EXPERIMENTAL
Intervention: Positive affect induction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control exercise
Number of subjects: 50
Study: 22985270

Group type: EXPERIMENTAL
Intervention: Low-dose inhaled corticosteroids (ICS)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Long-acting β2-agonists and anticholinergics
Number of subjects: 251
Study: 21411608

Group type: EXPERIMENTAL
Intervention: Richly fortified porridge (19 micronutrients)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Basal porridge (9 micronutrients)
Number of subjects: 743
Study: 19520393

Group type: EXPERIMENTAL
Intervention: Reconciliation Errors
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Unjustified discrepancies
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Reconciliation Error rate
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Total medications registered
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: No discrepancies
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Justified discrepancies
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Indeterminate errors
Number of subjects: 603
Study: 17382109

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment (starting dose, 5 mg/kg/day; median duration, 27.5 days)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 226

Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 226
Study: 15448036

Group type: EXPERIMENTAL
Intervention: BAY 43-9006 at 400 mg orally twice daily
Number of subjects: 41
Study: 12095057

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10212870

Group type: EXPERIMENTAL
Intervention: Bandage contact lens (BCL) applied to one tympanic membrane after removal of VTs
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conservative management (control group) of the other tympanic membrane after removal of VTs
Number of subjects: 39
Study: 7597016

Group type: EXPERIMENTAL
Intervention: Culturally sensitive health education videos displayed in waiting rooms during intervention weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control weeks (no video exposure).
Number of subjects: 0
Study: 2339965

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg every 8 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7011164

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine‐1% lidocaine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1% etidocaine‐1% lidocaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: bupivacaine alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: mixture of bupivacaine‐lidocaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: etidocaine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: mixture of etidocaine‐lidocaine
Number of subjects: 48
Study: 31344073

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 530

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 530
Study: 30387458

Group type: EXPERIMENTAL
Intervention: Herbal mouthwash
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 60
Study: 27659887

Group type: EXPERIMENTAL
Intervention: Pharmacist-led multicomponent intervention (behavioral interviewing, text messaging, mailed progress reports, video visits)
Number of subjects: 4076

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4076
Study: 25010374

Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 mg daily)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 22834953

Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD)
Number of subjects: 1128305
Study: 21050319

Group type: EXPERIMENTAL
Intervention: Rifaximin 1,100 mg once daily for 2 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rifaximin 1,100 mg once daily
Number of subjects: 100
Study: 17188121

Group type: EXPERIMENTAL
Intervention: Viewing a humorous video (87-min duration)
Number of subjects: 20
Study: 15764035

Group type: EXPERIMENTAL
Intervention: Evelle (proprietary oral supplement for skin nutrition)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 12271298

Group type: EXPERIMENTAL
Intervention: 5% lidocaine (ELA‐Max) cream applied after erbium:yttrium‐aluminum‐garnet (Er:YAG) laser ablation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Topical anesthesia alone
Number of subjects: 12
Study: 10023275

Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both anaesthesia types
Number of subjects: 30
Study: 8149518

Group type: EXPERIMENTAL
Intervention: Intensive cholesterol-lowering treatment for 90 days
Number of subjects: 12
Study: 2907408

Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29954340

Group type: EXPERIMENTAL
Intervention: Quarterly automated follow-up only (telemetry group)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Personal contact (remote+phone subgroup)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Personal contact (in-clinic visits only)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Overall mortality rates
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Overall HF-hospitalisation rates
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Telemetry and remote+phone groups
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Overall ICD therapy delivered
Number of subjects: 210
Study: 28859020

Group type: EXPERIMENTAL
Intervention: 2-stage nonoperative treatment with additional diagnostic block if regular 2 weeks medication was not effective
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs for 2 weeks
Number of subjects: 66
Study: 26553682

Group type: EXPERIMENTAL
Intervention: PsA‐TT vaccine
Number of subjects: 4004

Group type: COMPARATOR
Intervention: PsACWY vaccine
Number of subjects: 4004
Study: 24079117

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain lubricating gel
Number of subjects: 0
Study: 20206179

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (within 72 hours after ES)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (after 6-8 weeks)
Number of subjects: 96
Study: 18219532

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 390

Group type: COMPARATOR
Intervention: St. Mark's incontinence score
Number of subjects: 390
Study: 16875041

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (< 30 g/day)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Caloric-Restricted Diet (< 30% of calories from fat)
Number of subjects: 132
Study: 12544730

Group type: EXPERIMENTAL
Intervention: Idraparinux (2.5, 5, 7.5 or 10 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 37
Study: 10773785

Group type: EXPERIMENTAL
Intervention: CA19-9 in bronchoalveolar lavage fluid (BALF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Purified CA19-9
Number of subjects: 24
Study: 8638533

Group type: EXPERIMENTAL
Intervention: FLP (5-FU, leucovorin, cisplatin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FLAP (5-FU, leucovorin, cisplatin, Adriamycin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 8102631

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 3529368

Group type: EXPERIMENTAL
Intervention: Polyestradiol phosphate (Estradurin, Leo) 80 mg i.m. every fourth week + ethinyl estradiol (Etivex, Leo) 150 micrograms daily
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (Estracyt, Leo) 280 mg twice daily
Number of subjects: 244

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 244
Study: 29925324

Group type: EXPERIMENTAL
Intervention: Email invitation
Number of subjects: 401

Group type: COMPARATOR
Intervention: Postal invitation
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Vaccinated individuals
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Males 18-49 years old
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Respondents with local adverse events
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Respondents with systemic adverse events
Number of subjects: 401
Study: 27433335

Group type: EXPERIMENTAL
Intervention: 6-week self-management training program (manual therapy, education, home exercises) with instructional workbook and video and a pedometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single instructional session with instructional workbook and video and pedometer
Number of subjects: 0
Study: 25662413

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m², four weekly infusions)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 112
Study: 23279058

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 22
Study: 21606869

Group type: EXPERIMENTAL
Intervention: Maximal-effort graded exercise test
Number of subjects: 70
Study: 19115653

Group type: EXPERIMENTAL
Intervention: Pelvic wedge (group P)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lumbar wedge (group L)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16469211

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tissucol) applied on the gastro‐jejunal and jejuno‐jejunal anastomoses and the mesenteric openings
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (no fibrin glue, but suture of the mesenteric openings)
Number of subjects: 322
Study: 12957701

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation using Integrated Psychological Treatment (IPT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (10 patients without cognitive impairments)
Number of subjects: 27
Study: 10966535

Group type: EXPERIMENTAL
Intervention: Negative T waves (NT group, n = 938, 62%)
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Positive T waves (PT group, n = 567, 38%)
Number of subjects: 1505

Group type: EXPERIMENTAL
Intervention: Negative T waves (NT group)
Number of subjects: 1505
Study: 9192196

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (3-4 mg of elemental iron per kg body weight, 1 day per week)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (3-4 mg of elemental iron per kg body weight, 5 days per week)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 8243685

Group type: EXPERIMENTAL
Intervention: Kallidinogenase (600 units by mouth daily for 12 weeks)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 3519529

Group type: EXPERIMENTAL
Intervention: Propranolol (60-320 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Propranolol (60-240 mg or 320 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Propranolol (up to 320 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 29428785

Group type: EXPERIMENTAL
Intervention: Iron-folic acid supplements
Number of subjects: 17870

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements
Number of subjects: 17870

Group type: COMPARATOR
Intervention: Folic acid supplements only
Number of subjects: 17870
Study: 29322301

Group type: EXPERIMENTAL
Intervention: DHEA (100 mg daily for 4 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 27241898

Group type: EXPERIMENTAL
Intervention: Hands-on training
Number of subjects: 120

Group type: COMPARATOR
Intervention: No training
Number of subjects: 120
Study: 24105456

Group type: EXPERIMENTAL
Intervention: Oropharyngeal care with povidone-iodine (n = 91)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo (n = 88)
Number of subjects: 179
Study: 21951278

Group type: EXPERIMENTAL
Intervention: Orofacial exercise program (daily manual mouth-stretching and oral-augmentation exercises twice a day for 6 minutes for 6 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual dental care (control group)
Number of subjects: 48
Study: 18832434

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flupentixol 0.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17593148

Group type: EXPERIMENTAL
Intervention: Skills for Social and Academic Success (SASS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Educational-supportive treatment (control)
Number of subjects: 36
Study: 15957829

Group type: EXPERIMENTAL
Intervention: Astragalus injection (AGI)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 84
Study: 12397530

Group type: EXPERIMENTAL
Intervention: Felted foam therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 61
Study: 10363538

Group type: EXPERIMENTAL
Intervention: Nasogastric tube supplementation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bottle supplementation
Number of subjects: 84
Study: 7774190

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 1% in ethanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 0
Study: 1580032

Group type: EXPERIMENTAL
Intervention: 12F Foley catheter introduced after anesthesia prior to surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: 12F Foley catheter introduced after termination of cardiopulmonary bypass period
Number of subjects: 62

Group type: COMPARATOR
Intervention: Suprapubic catheter introduced after termination of the bypass period
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 12F Foley catheter introduced after anesthesia (in a larger group of 39 patients)
Number of subjects: 62
Study: 6233546

Group type: EXPERIMENTAL
Intervention: 2 puffs of fenoterol (100 micrograms) and ipratropium bromide (40 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 puffs of fenoterol (100 micrograms) and ipratropium bromide (40 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 puffs of fenoterol (100 micrograms) and ipratropium bromide (40 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 8 puffs of fenoterol (100 micrograms) and ipratropium bromide (40 micrograms)
Number of subjects: 20
Study: 31322563

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA) for adverse event monitoring
Number of subjects: 24
Study: 29052766

Group type: EXPERIMENTAL
Intervention: l-arginine supplementation (6.4 g orally/day)
Number of subjects: 144

Group type: COMPARATOR
Intervention: placebo therapy
Number of subjects: 144
Study: 26803328

Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 + DTaP/IPV
Number of subjects: 749

Group type: COMPARATOR
Intervention: saline + DTaP/IPV
Number of subjects: 749
Study: 25335172

Group type: EXPERIMENTAL
Intervention: Combination treatment (nortriptyline and/or gabapentin plus physical therapies, up to three cervical epidural steroid injections)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Epidural steroid injections (ESI)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 169
Study: 22507091

Group type: EXPERIMENTAL
Intervention: Cell Block (CB) method
Number of subjects: 170

Group type: COMPARATOR
Intervention: Smear cytology
Number of subjects: 170
Study: 20420616

Group type: COMPARATOR
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sustained hemodiafiltration (S-HDF)
Number of subjects: 60
Study: 18696354

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16101852

Group type: EXPERIMENTAL
Intervention: Resident-oriented care model
Number of subjects: 0
Study: 12269877

Group type: EXPERIMENTAL
Intervention: Glycolic acid peels combined with modified Kligman's formula (hydroquinone 5%, tretinoin 0.05%, hydrocortisone acetate 1%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified Kligman's formula (hydroquinone 5%, tretinoin 0.05%, hydrocortisone acetate 1%)
Number of subjects: 40
Study: 10073637

Group type: EXPERIMENTAL
Intervention: Cibasoft contact lens
Number of subjects: 10

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acuvue contact lens
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biomedics contact lens
Number of subjects: 10
Study: 8672931

Group type: EXPERIMENTAL
Intervention: Continuous i.v.‐tocolysis and oral application of magnesium sulfate
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Continuous i.v.‐tocolysis and i.v.‐application of magnesium sulfate
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pulsatile i.v.‐application of fenoterol (bolus tocolysis) and oral application of magnesium sulfate
Number of subjects: 59
Study: 1828309

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Thiopentone 4 mg/kg
Number of subjects: 52